Biophytis Targets Mobility Restoration in Patients with Obesity
Biophytis SA is strengthening its position in developing treatments for preserving muscle function in patients with obesity treated with GLP-1 therapies. The company's drug candidate BIO101, when combined with GLP-1 medications, has shown promising preclinical results in enabling high-quality weight loss while improving muscle function and strength.
While GLP-1 treatments are effective for weight loss, they can cause concerning muscle mass loss. Biophytis aims to address this issue by focusing on quality weight loss - reducing fat while preserving muscle mass and improving mobility. The company is targeting a specific market segment of obesity patients using GLP-1 therapies, with the global obesity market projected to reach $100 billion by 2030.
This development addresses a significant unmet need, as 96% of obesity patients experience muscle strength impairment. Biophytis positions itself as the only market player primarily focused on muscle quality and mobility restoration in combination with GLP-1 treatments.
Biophytis SA sta rafforzando la sua posizione nello sviluppo di trattamenti per preservare la funzione muscolare nei pazienti con obesità trattati con terapie GLP-1. Il candidato farmaco dell'azienda, BIO101, combinato con i farmaci GLP-1, ha mostrato risultati preclinici promettenti, permettendo una perdita di peso di qualità elevata migliorando al contempo la funzione e la forza muscolare.
Nonostante i trattamenti con GLP-1 siano efficaci per la perdita di peso, possono causare una preoccupante perdita di massa muscolare. Biophytis si propone di risolvere questo problema puntando a una perdita di peso di qualità, riducendo il grasso corporeo, preservando la massa muscolare e migliorando la mobilità. L'azienda si rivolge a un segmento specifico di pazienti con obesità che utilizzano terapie GLP-1, con un mercato globale dell'obesità previsto raggiungere 100 miliardi di dollari entro il 2030.
Questa innovazione risponde a un bisogno importante e non soddisfatto, poiché il 96% dei pazienti obesi presenta un deficit di forza muscolare. Biophytis si posiziona come l'unico attore di mercato focalizzato principalmente sulla qualità muscolare e sul recupero della mobilità in combinazione con i trattamenti GLP-1.
Biophytis SA está fortaleciendo su posición en el desarrollo de tratamientos para preservar la función muscular en pacientes con obesidad tratados con terapias GLP-1. El candidato a medicamento de la compañía, BIO101, combinado con medicamentos GLP-1, ha mostrado resultados preclínicos prometedores, permitiendo una pérdida de peso de alta calidad mientras mejora la función y la fuerza muscular.
Aunque los tratamientos con GLP-1 son efectivos para la pérdida de peso, pueden causar una preocupante pérdida de masa muscular. Biophytis busca abordar este problema enfocándose en una pérdida de peso de calidad, reduciendo la grasa corporal, preservando la masa muscular y mejorando la movilidad. La empresa apunta a un segmento específico de pacientes con obesidad que usan terapias GLP-1, con un mercado global de obesidad proyectado a alcanzar los 100 mil millones de dólares para 2030.
Este desarrollo responde a una necesidad significativa no cubierta, ya que el 96% de los pacientes con obesidad presenta deterioro en la fuerza muscular. Biophytis se posiciona como el único actor del mercado enfocado principalmente en la calidad muscular y la restauración de la movilidad en combinación con los tratamientos GLP-1.
Biophytis SA는 GLP-1 치료를 받는 비만 환자의 근육 기능 보존을 위한 치료제 개발 분야에서 입지를 강화하고 있습니다. 회사의 약물 후보물질인 BIO101은 GLP-1 약물과 병용 시 고품질 체중 감량과 근육 기능 및 근력 향상에 있어 유망한 전임상 결과를 보여주었습니다.
GLP-1 치료는 체중 감량에 효과적이지만, 근육량 감소라는 우려되는 부작용이 있습니다. Biophytis는 지방은 줄이면서 근육량을 보존하고 이동성을 개선하는 고품질 체중 감량에 집중하여 이 문제를 해결하고자 합니다. 회사는 GLP-1 치료를 받는 비만 환자라는 특정 시장 세그먼트를 목표로 하고 있으며, 전 세계 비만 시장은 2030년까지 1,000억 달러에 이를 것으로 예상됩니다.
이 개발은 비만 환자의 96%가 근력 저하를 경험한다는 중요한 미충족 수요를 해결합니다. Biophytis는 GLP-1 치료와 병용하여 근육 품질과 이동성 회복에 주로 집중하는 유일한 시장 참여자로 자리매김하고 있습니다.
Biophytis SA renforce sa position dans le développement de traitements visant à préserver la fonction musculaire chez les patients obèses traités par thérapies GLP-1. Le candidat-médicament de l'entreprise, BIO101, associé aux médicaments GLP-1, a montré des résultats précliniques prometteurs permettant une perte de poids de qualité tout en améliorant la fonction et la force musculaire.
Bien que les traitements GLP-1 soient efficaces pour la perte de poids, ils peuvent entraîner une perte préoccupante de masse musculaire. Biophytis cherche à résoudre ce problème en se concentrant sur une perte de poids qualitative – réduction de la masse grasse tout en préservant la masse musculaire et en améliorant la mobilité. L'entreprise cible un segment spécifique de patients obèses sous thérapies GLP-1, avec un marché mondial de l'obésité prévu atteindre 100 milliards de dollars d'ici 2030.
Ce développement répond à un besoin majeur non satisfait, puisque 96 % des patients obèses souffrent d'une altération de la force musculaire. Biophytis se positionne comme le seul acteur du marché principalement dédié à la qualité musculaire et à la restauration de la mobilité en association avec les traitements GLP-1.
Biophytis SA stärkt seine Position in der Entwicklung von Behandlungen zur Erhaltung der Muskelfunktion bei adipösen Patienten, die mit GLP-1-Therapien behandelt werden. Der Arzneimittelkandidat des Unternehmens, BIO101, hat in Kombination mit GLP-1-Medikamenten vielversprechende präklinische Ergebnisse gezeigt, die eine qualitativ hochwertige Gewichtsabnahme ermöglichen und gleichzeitig die Muskelfunktion und -kraft verbessern.
Obwohl GLP-1-Behandlungen effektiv zur Gewichtsreduktion sind, können sie einen besorgniserregenden Muskelmasseverlust verursachen. Biophytis verfolgt das Ziel, dieses Problem anzugehen, indem es auf eine qualitativ hochwertige Gewichtsabnahme abzielt – Fettabbau bei gleichzeitiger Erhaltung der Muskelmasse und Verbesserung der Mobilität. Das Unternehmen fokussiert sich auf ein spezifisches Marktsegment von Adipositas-Patienten, die GLP-1-Therapien nutzen, wobei der globale Adipositas-Markt voraussichtlich bis 2030 100 Milliarden US-Dollar erreichen wird.
Diese Entwicklung adressiert einen bedeutenden ungedeckten Bedarf, da 96 % der adipösen Patienten eine Beeinträchtigung der Muskelkraft erleben. Biophytis positioniert sich als einziger Marktteilnehmer, der sich hauptsächlich auf die Muskelqualität und die Wiederherstellung der Mobilität in Kombination mit GLP-1-Behandlungen konzentriert.
- Promising preclinical results for BIO101 in combination with GLP-1 therapies
- Targeting large market opportunity of $100 billion by 2030
- Unique market position as only player focused on muscle quality and mobility restoration
- Addresses critical unmet need affecting 96% of obesity patients
- Still in preclinical stage, indicating long path to market approval
- Will face competition from major pharmaceutical companies in obesity space
- Success dependent on clinical trial outcomes not yet demonstrated
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients' mobility, strength, and quality of life. It is now essential to move beyond viewing weight loss purely in quantitative terms and focus instead on the quality of weight loss-meaning the reduction of fat mass while preserving muscle mass and improving functional mobility. The development of BIO101 in combination with GLP-1 medications is fully aligned with this goal.
The recently disclosed preclinical results demonstrate that the drug candidate BIO101, in combination with GLP-1 therapies, enables high-quality weight loss and improves muscle function and strength.
Biophytis is thus specifically targeting a high-value subpopulation: patients with obesity treated with GLP-1 therapies. Thanks to its mechanism of action, BIO101 paves the way for a new generation of combination treatments focused on the quality of weight loss and the restoration of mobility for patients.
In a global obesity market projected to reach
Stanislas Veillet, CEO of Biophytis, stated: "GLP-1 treatments have marked a major step forward in the fight against obesity, but they expose patients to a loss of muscle mass, which can have serious consequences. BIO101 is a game-changer because it should allow when combined with GLP-1 not only for weight loss, but also for preserving muscle mass and improving mobility. This is a unique opportunity for Biophytis to address an unmet medical need in a rapidly expanding market."
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.
Biophytis Contacts
Investor Relations
Investors@biophytis.com
US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78
________________________
1 Source : Goldman Sachs Intelligence, Anti-obesity market
2 Source : Valenzuela et al. BMC Musculoskeletal Disorders (2020) 21:200, (2) Obesity management strategies should cut fat, not muscle | International Journal of Obesity
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249265
FAQ
What are the key benefits of Biophytis' BIO101 when combined with GLP-1 therapy for obesity?
How large is the market opportunity for Biophytis' obesity treatment solution?
What distinguishes Biophytis (BPTSY) from other companies in the obesity treatment market?
What clinical stage is BIO101 currently in for obesity treatment?
